Larotrectinib and its Impurities
Larotrectinib (tradename Vitrakvi) is a drug for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Reference standards of Larotrectinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.